At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed recurrent high-grade Ewing's sarcoma with progressive disease after standard therapy
- ✓Histologically confirmed high-grade osteosarcoma (closed to accrual as of 12/21/06) with progressive disease after standard therapy
- ✓Histologically confirmed unresectable or locally recurrent chondrosarcoma unable to be completely resected
- ✓At least 1 unidimensionally measurable lesion by medical imaging techniques
- ✕More than 2 additional salvage regimens for Ewing's sarcoma or osteosarcoma
- ✕Prior gemcitabine therapy
- ✕Prior taxane therapy
- ✕Prior allogeneic transplantation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewing's Sarcoma, Osteosarcoma, Or Unresectable Or Locally Recurrent Chondrosarcoma [SARC Study]
In Brief
A Phase 2 clinical trial evaluating filgrastim, pegfilgrastim, and 5 other interventions for Sarcoma. Completed, enrolled 54 participants.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with docetaxel in treating patients who have recurrent osteosarcoma, recurrent Ewing's sarcoma, or unresectable or locally recurrent chondrosarcoma.
Study Details
Timeline
Interventions
filgrastim
pegfilgrastim
docetaxel
gemcitabine hydrochloride
microarray analysis
laboratory biomarker analysis
pharmacokinetic study